

TYPE	DISEASE	TRIAL	PI	TITLE
Lung	ALCHEMIST screening trial	A151216	Dissanayake, R. MD	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
	Lung (ALCHEMIST Sub-study)	E4512	Dissanayake, R. MD	A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer . Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
	Stage III Lung	CA209-73L	Watkins, James MD	A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
	Met. Adeno	EA5163/S1709	Watkins, James MD	A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
	Small Cell Lung	NRG-LU005	Eldawy, Tarek MD	Limited Stage Small Cell Lung Cancer (LS-SCLC) : A Phase II/III Randomized Study of Chemoradiation versus Chemoradiation plus Atezolizumab (01-OCT-2019)
Breast	Adjuvant HER2+ Breast	A011801	Eldawy, Tarek MD	The COMPASSHER2 Trials (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT to OPTIMIZE THERAPY in HER2-POSITIVE BREAST CANCER): COMPASSHER2 Residual Disease (RD) , A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and TUCATINIB
	Met. ER/PR+ HER2- Breast	SWOG S1703	El-Sayah, Dany MD	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
	Breast	SWOG S1706	Watkins, James MD	A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
CLL	CLL	S1925	Alsayed, Yazan MD	*Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) : EVOLVE CLL/SLL Study
GI	Met. Anal	EA2176	Dissanayake, R. MD	A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
H&N	Recurrent H&N	EA3191	Watkins, James MD	A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Melanoma	Stage III-IV resected Melanoma	CA224-098	Eldawy, Tarek MD	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
	Unresectable Melanoma	HBI-8000-303	Wright, Zachary, MD	A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors
MM	New Dx MM	EAA181	Brown, Alexander MD	Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation
Supportive Care	MDS/AML/MF	CONNECT Myeloid	Alsayed, Yazan MD	Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
	Solid Tumor Malignancy	S2013	El-Sayah, Dany MD	IMMUNE CHECKPOINT INHIBITOR TOXICITY (I-CHECKIT) : A PROSPECTIVE OBSERVATIONAL STUDY
	Solid Tumor Malignancy	BESPOKE-IO	Watkins, James MD	BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO)